Risk factors associated with bloodstream infections among critically ill patients with COVID-19
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
The Journal of infection - 83(2021), 5 vom: 20. Nov., Seite e1-e3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McMillan, Tim [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bloodstream infection |
|---|
| Anmerkungen: |
Date Completed 30.11.2021 Date Revised 04.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2021.09.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330792458 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330792458 | ||
| 003 | DE-627 | ||
| 005 | 20231225212040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2021.09.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330792458 | ||
| 035 | |a (NLM)34537320 | ||
| 035 | |a (PII)S0163-4453(21)00480-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McMillan, Tim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors associated with bloodstream infections among critically ill patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2021 | ||
| 500 | |a Date Revised 04.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Bloodstream infection | |
| 650 | 4 | |a Corticosteroid | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Tocilizumab | |
| 700 | 1 | |a Jones, Conor |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connor, Cavan J |e verfasserin |4 aut | |
| 700 | 1 | |a Nolan, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Xin Hui S |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Jayne |e verfasserin |4 aut | |
| 700 | 1 | |a Thakker, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Kranzer, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Neil Rh |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Mervyn |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, A Peter R |e verfasserin |4 aut | |
| 700 | 1 | |a Arulkumaran, Nishkantha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 83(2021), 5 vom: 20. Nov., Seite e1-e3 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2021 |g number:5 |g day:20 |g month:11 |g pages:e1-e3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2021.09.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2021 |e 5 |b 20 |c 11 |h e1-e3 | ||